Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics

By Colin KellaherMerck & Co. has agreed to license a potential cancer treatment from SciBrunch Therapeutics in a deal that could be worth more than $2 billion to the privately held clinical-stage biotechnology company.Merck on Monday said the agreement gives the Rahway, N.J., drugmaker exclusive wo…